Top Markets
Coin of the day
TaiwanJ Pharmaceuticals Co., Ltd. TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd.

6549
Rang in Aktien #30194
TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm... TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm dedicated to the research, development, and commercialization of small molecule therapeutics. Initially, its focus within Taiwan has been on tackling chronic organ inflammation stemming from metabolic, autoimmune, or infectious causes. The company's growing pipeline also features specific compounds like JKB-122 and JKB-121, alongside a collection of innovative chemical entities. These new drugs are being developed to address persistent liver conditions and allergic respiratory ailments, such as asthma. TaiwanJ's comprehensive product portfolio is engineered to combat a wide array of diseases, encompassing hepatic inflammation and fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), various autoimmune disorders, asthma, and atopic dermatitis (eczema). Established in 2011, the company's operations are headquartered in Zhubei, Taiwan.
Aktienkurs
$0.21877731
Marktkapitalisierung
$17.53M
Veränderung (1 Tag)
-1.57%
Veränderung (1 Jahr)
-16.15%
Land
TW
Handel TaiwanJ Pharmaceuticals Co., Ltd. (6549)

Kategorie

Dividendenrendite-Verlauf für TaiwanJ Pharmaceuticals Co., Ltd. (6549)
Dividendenrendite (TTM) von TaiwanJ Pharmaceuticals Co., Ltd. (Aktienkürzel: 6549) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für TaiwanJ Pharmaceuticals Co., Ltd. (6549) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber